Ocular Drug Delivery System Development Service

One of the main challenges in ocular drug delivery is the limited permeability of the cornea and conjunctiva, which prevents many drugs from reaching their intended targets. Dendrimers can be used to overcome this limitation by encapsulating drugs and enhancing their permeability through the ocular tissue. CD BioSciences is a specialized CRO with a comprehensive service chain in the development of a wide range of novel dendrimers. With expertise in organic chemistry and biomedical sciences, we have successfully completed many development projects for novel dendrimers for ocular drug delivery, providing high quality customized services based on a full range of advanced technologies. We are committed to helping our customers worldwide to reduce the development time of novel dendrimers in the least costly way.

Nanomaterials for Ocular Drug Delivery

Nanotechnology has emerged as a promising field for developing advanced drug delivery systems, including those targeted towards the eye. Ocular drug delivery poses several challenges such as poor bioavailability, short residence time, and susceptibility to rapid clearance from the eye. Nanomaterials offer several advantages over conventional drug delivery systems such as enhanced bioavailability, prolonged drug release, targeted delivery, and improved therapeutic efficacy. Some of the commonly used nanomaterials for ocular drug delivery include liposomes, nanoparticles, dendrimers, and nanofibers.

Various nanocarriers for ocular drug delivery. (Razavi MS, et al., 2022)

Dendrimers for Ocular Drug Delivery

The unique properties of dendrimers, such as highly branched three-dimensional structures and the ability to be precisely designed, make them an attractive option for ocular drug delivery, not only for improving the bioavailability of drugs, but also for targeting specific tissues in the eye. Ocular drug delivery using dendrimers has shown promising results due to their unique properties, such as high-water solubility, low toxicity, and the ability to penetrate biological barriers.

• For Anterior and Posterior Drug Delivery
  Dendrimers can be used for both anterior and posterior ocular drug delivery. For anterior ocular delivery, dendrimers can be used to improve the bioavailability of drugs delivered via eye drops by enhancing drug penetration through the cornea and improving drug retention in the ocular tissues. For posterior ocular delivery, dendrimers can be used to deliver drugs to the retina, which is challenging due to the blood-retinal barrier.
• Regulating Interaction with Ocular Tissues
  Dendrimers can be engineered to have different surface charges, which can be used to tailor their interaction with ocular tissues. For example, cationic dendrimers can interact with the negatively charged corneal epithelium and improve drug penetration, while anionic dendrimers can interact with positively charged vitreous proteins and improve drug retention.
• Increasing Specificity
  Additionally, dendrimers can be functionalized with targeting ligands, such as antibodies or peptides, to further improve their specificity for ocular tissues. For example, dendrimers functionalized with a targeting peptide that binds to retinal pigment epithelium cells have been shown to improve drug delivery to these cells.

Process of Dendrimers Development for Ocular Drug Delivery System

In the field of ocular drug delivery, dendrimers have shown promise as a means of improving the delivery of drugs to the eye. The eye is a challenging target for drug delivery due to the presence of various barriers, such as the cornea, conjunctiva, and blood-retinal barrier. Dendrimers can potentially overcome these barriers by penetrating the tissues and reaching the desired site of action. The development of dendrimers for ocular drug delivery involves several steps, including synthesis, characterization, and evaluation of their biocompatibility, toxicity, and efficacy. Some of the factors that need to be considered during the development process include the dendrimer's size, charge, surface functionality, and biodegradability.

Our Services

The development of dendrimers for ocular drug delivery is an exciting area of research that has the potential to improve the treatment of a variety of ocular diseases. CD BioSciences currently has a dedicated team in place to assist our customers with their novel dendrimer development projects. With many advanced technologies and years of experience, we can develop the most appropriate strategy to meet each of your specific needs.

Advantages of Our Services

Want to Learn More?

With years of experience in dendrimer research, CD BioSciences provides high quality, hassle-free, cost-effective services, and innovative products for dendrimer research. Our integrated, customer-focused team will anticipate challenges, overcome obstacles, and deliver quality-tested results on time. For more information, please feel free to contact us or send us an inquiry.

Reference

1. Razavi MS, et al., Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds. Front Chem. 2022, 10: 850757.